EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alcon's Enterprise Value is $37,160 Mil.
Alcon's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $584 Mil. Therefore, Alcon's EV-to-EBIT for today is 63.63.
The historical rank and industry rank for Alcon's EV-to-EBIT or its related term are showing as below:
ALC'
s EV-to-EBIT Range Over the Past 10 Years
Min: -168.06 Med: -51.48 Max: 121.64
Current: 63.45
During the past 6 years, the highest EV-to-EBIT of Alcon was 121.64. The lowest was -168.06. And the median was -51.48.
ALC's EV-to-EBIT is ranked worse than 90.32% of 434
companies
in the Medical Devices & Instruments industry
Industry Median: 20.46
vs ALC: 63.45
The historical data trend for Alcon's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Alcon Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-EBIT
-
-
-137.81
-69.14
85.25
Alcon Quarterly Data
Dec16
Dec17
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EV-to-EBIT
106.01
87.25
85.25
68.28
65.50
Competitive Comparison
For the Medical Instruments & Supplies subindustry, Alcon's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon EV-to-EBIT Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alcon's EV-to-EBIT falls into.
Alcon's current Enterprise Value is $37,160 Mil.
Alcon's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $584 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon (NYSE:ALC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alcon's Enterprise Value for the quarter that ended in Jun. 2022 was $37,601 Mil.
Alcon's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $584 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Alcon's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.06(0.09%) Volume: 672,851 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:ALC has been successfully added to your 
